A Study Evaluating the Safety and Efficacy of the BD211 Drug Product in β-Thalassemia Major Participants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

2 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-07-10

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Phase 1,open label,safety,and efficacy study in subjects with non-β0/β0 TDT β-thalassemia Major by transplanting BD211 drug product which is for autologous use only,via a single IV administration.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Major

NCT06465550

β-thalassemia

RECRUITING PHASE1

Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent Beta-thalassemia

NCT05773729

β-thalassemia

RECRUITING NA

Gene Therapy of Beta Thalassemia Using a Self-inactivating Lentiviral Vector

NCT03351829

Beta-Thalassemia

UNKNOWN NA

A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in β-Thalassemia Major Participants

NCT01745120

β-thalassemia Major

COMPLETED PHASE1/PHASE2

A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia, Who do Not Have a β0/β0 Genotype

NCT02906202

Beta-Thalassemia

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

After collection of mobilised peripheral blood samples, the patient's autologous cells,enriched for CD34+ HSCs, undergo ex vivo transduction with lentiviral vector encoding βA-T87Q-globin to BD211 finished product,which is then infused intravenously into the patient after myeloablative busulfan conditioning to prepare bone marrow "niches" for engraftment of the HSCs.

After discharge, subjects will be followed monthly, at a minimum, for 6 months and thereafter every 3 months for the remainder of the 24 months post-transplant.

Evaluation will include Routine and special biological testing at regular intervals, collection of AEs and concomitant medications, and evaluation of disease specific biological and clinical parameters.

Subjects will then be enrolled in a long-term follow-up protocol with annual evaluations for an additional 13 years post-transplant.

The long-term follow-up study will focus on long-term safety, with an emphasis on integration site analysis, and long-term efficacy.

This study will end when the last subject completes the Month 24 visit or discontinues from the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hematologic Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Mobilization,harvest,transduction,conditioning,treatment,engraftment

Subjects will participate in this study for a total of approximately 27 months, consisting of an up to 3 months pre-transplant period(consisting of a screening period followed by autologous cell harvest, followed by a waiting period during which the harvested cells are transduced and undergo release testing, followed by treatment with busulfan IV, and a single infusion of BD211 Drug Product) and a 24-month post-transplant evaluation period. Following completion of this study, all subjects will be asked to provided consent to participate in a follow-up study for another 13 years, which will focus on long-term safety, with an emphasis on integration site analysis, and long-term efficacy.

Group Type EXPERIMENTAL

BD211 Drug Product

Intervention Type GENETIC

Transplantation of Autologous CD34+Stem Cells Transduced to BD211 finished Product with a Lentiviral Vector coding βA-T87Q-Globin.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BD211 Drug Product

Transplantation of Autologous CD34+Stem Cells Transduced to BD211 finished Product with a Lentiviral Vector coding βA-T87Q-Globin.

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. 5 to 35 years of age.
2. Be eligible for allogeneic HSCT based on institutional medical guideline, but without a matched related donor.
3. Transfusion-dependent β-Thalassemia Major, regardless of the genotype, with the diagnosis confirmed by Hb studies. Subjects must be stable and maintained on an appropriate iron chelation regimen. Transfusion dependence is defined as requiring at least 100 mL/kg/year of packed red blood cells(pRBCs).
4. Have been treated and followed for at least the past 2 years in a specialized center that maintained detailed medical records, including transfusion history.
5. Be willing and able, in the Investigator's opinion, to comply with the study procedures outlined in the study protocol. If a pediatric subject, the subject's parent/legal guardian also must be willing and able to comply with the study procedures outlined in the study protocol.

Exclusion Criteria

1. Availability of a willing matched HLA-identical sibling hematopoietic cell donor.
2. Positive for presence of human immunodeficiency virus, human T-lymphotropic virus, vesicular stomatitis virus G antibody.
3. Clinically significant, active bacterial, viral, fungal, or parasitic infection.
4. A white blood cell (WBC) count\<3x109/L and/or platelet count\<120x109/L
5. Receipt of an allogeneic transplant.
6. Receipt of erythropoietin within 3 months before HSCT harvest.
7. Contraindication to anesthesia for bone marrow harvesting.
8. Any of prior or current malignancy, myeloproliferative or immunodeficiency disorder.
9. Active relapsing malaria
10. Immediate family member with a known or suspected Familial Cancer Syndrome.
11. Diagnosis of significant psychiatric disorder of the subject that could seriously impede the ability to participate in the study.
12. Pregnancy or breastfeeding in a postpartum female or absence of adequate contraception for fertile subjects.
13. Any other condition that would render the subject ineligible for HSCT, as determined by the attending transplant physician.
14. History of major organ damage.including Liver, Heart, Kidney disease, pulmonary hypertension ,severe iron overload, which in the opinion of the physician is grounds for exclusion.
15. Participation in another clinical study with an investigational drug within 30 days of screening.
16. Hydroxyurea therapy within 3 months before hematopoietic stem cell collection.
17. An assessment by the Investigator that the subject or parents of the subject will not comply with the study procedures outlined in the study protocol.
18. Subjects who have the desire to become a parent within the 27-month study period.
19. Prior receipt of gene therapy.

Minimum Eligible Age

5 Years

Maximum Eligible Age

35 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No